CISSPECT DESK-LAB

The world's first fully automated synthesis module

22 July 2020

The automated DESK-LAB process:

Ensures a high quality reproduction of each radiopharmaceutical batch

Reduces and simplifies the handling of radioactive material by the radiochemistry lab scientists

Automated GMP synthesis at your desk!

CISSPECT DESK-LAB represents a great leap forward for the development of radiopharmaceuticals and personalised drug discovery. Recently, we have developed the world’s first fully automated synthesis module, CISSPECT DESK-LAB, for the synthesis of Pt-195m cisplatin and other platinum compounds

The module has been designed for the production of GMP Pt-195m Cisplatin to facilitate a human pilot study. We have achieved this in close collaboration with our industrial partner FutureChemistry and renowned Dutch Academic Medical Centres.

process steps leading to results

DISSOLVE
DISSOLVE
Step 1
REDUCE
REDUCE
STEP 2
IODINATE
IODINATE
STEP 3
AMINATE
AMINATE
STEP 4
HYDROLYSE
HYDROLYSE
STEP 5
CHLORINATE
CHLORINATE
STEP 6
DISPENSE
DISPENSE
STEP 7

Results

drag for more

Fully automated synthesis of Pt-195m cisplatin

For the GMP production of various Platinum compounds

Automated dispensing into patient doses

In addition to the Dhara synthesis according to Hoeschele et. al., Radiochimica Acta 1982

Partner: FutureChemistry

FutureChemistry Holding B.V. develops, builds and implements equipment and processes for manufacturing of chemicals with a high added value. With a focus in particular on two product groups: nanomaterials and radiopharmaceuticals.

  • Located at the Technology and Science Park of the Radboud University Nijmegen
  • Years of experience in flow chemistry

“A great leap forward for the development of radiopharmaceuticals and personalised drug discovery.“

CISSPECT = Pt-195m = radioactive cisplatin

The main draw backs of cisplatin chemotherapy treatment is kidney toxicity, as well as the low response rate in many cases, which cannot be predicted beforehand. Pt-195m cisplatin, or CISSPECT, is developed to enable quantification of the in vivo bio distribution of cisplatin, a standard chemotherapeutic agent. Pt-195m cisplatin may be able to select patients who will not respond to cisplatin chemotherapy, or those patients who will suffer from severe kidney toxicity due to cisplatin treatment.

CISSPECT® DESK-LAB - Automated GMP synthesis at your desk!

Human Pilot

The feasibility of SPECT imaging and quantification of Pt-195m in a preclinical setting has already been  shown (E.A. Aalbersberg et al., EJNMMI 2017 (44), 8, 1347 – 1354). As a next step, the feasibility in humans will be assessed. If successful, Pt-195m cisplatin contributes to optimising treatment outcome of chemo(radio)therapy and reducing toxicity in a personalised approach.

Relevant produts

  • High specific activity
  • Reliable synthesis
  • For human use
Read more
  • No additional transport required from the reactor
  • Produced in parallel with molybdenum-99
  • Low enrichted uranium based (LEU)
Read more